The reduction of IL6 serum level after four months of COVID- 19 infection in the medical staff of Neurosurgery Teaching Hospital in Baghdad
Keywords:
Covid-19, Neurosurgery Teaching Hospital, IL-6 serum levels, One month, four months.Abstract
Background: SARS-CoV-2, the causative agent of COVID-19, was first detected in Wuhan, China, in late 2019 in a cluster of patients with pneumonia. Accumulatively and until July 2022, Iraq registered 2,438,101 million COVID-19 cases and 25,304 deaths putting Iraq in third place among the Eastern Mediterranean Sea countries.The pathophysiological hallmark of COVID is closely associated with severe inflammatory responses; thereby, identifying the serum level of IL-6 may predict the progression of COVID-19 disease. Materials and Methods: This study included ninety volunteered medical staff who worked in the Neurosurgery Teaching Hospital and were diagnosed with COVID-19 by PCR and accepted to give 5 ml of their blood. The medical staff was categorized into two groups and every group contain forty-five, we collected blood from the first group after one month (30 days) from the day of COVID-19 infection diagnosis while the second group after 4 months (120 days). we used a Quantikine IL-6 ELISA kit (catalogs numbers D6050 56050 PD6050) which is a sandwich ELISA and according to the manufacturer to estimate the serum levels of Human IL-6. Results: The independent two-sample Mann–Whitney test was used which showed that there was a significant decrease (P<0.05) in the IL-6 serum levels of the volunteered Medical staff after 4 months when it is compared to the one month Conclusion:IL6 serum levels decreased significantly after 120 days (4months) of COVID-19 infection.
Downloads
References
Kahn, J.S. and McIntosh, K., 2005. History and recent
advances in coronavirus discovery. The Pediatric
infectious disease journal, 24(11), pp. S223-S227.
World Health Organization. (2006).The world health report 2006:
working together for health.World Health Organization.
Holmes, E.C., and Rambaut, A., 2004. Viral evolution and the
emergence of SARS coronavirus. Philosophical
Transactions of the Royal Society of London. Series B:
Biological Sciences, 359(1447), pp.1059-1065.
Chen, L., Deng, H., Cui, H., Fong, J., Zuo, Z., Deng, J., Li, Y., Wong, X.
and Zhao, L, 2018. Inflammatory responses and inflammationassociated diseases in organs.Oncotarget,9(6),p.7204.
Hirano T, Murakami M. COVID-19: a new virus, but a familiar
receptor and cytokine release syndrome. Immunity.
; 52(5): 731-3.
COVID-19 infection: an overview on cytokine storm and related
interventions SoheilaMontazersahebl, Seyed Mahdi
HosseiniyanKhatibi2, Mohammad Saeid Hejazil,
VahidehTarhrizI, AfsanehFarjami3,
FaramarzGhasemianSorbeni4, Raheleh Farahzadi5*+ and
TohidGhasemnejadl
Kimura A, Kishimoto TJ. IL-6: regulator of Treg/Th17
balance. Eur J Immunol. 2010;40(7):1830-5.
Jones BE, Maerz MD, Buckner JHJ. IL-6: a cytokine at the
crossroads of autoimmunity. CurrOpinlmmunol. 2018;
: 9-14.
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a
systematic review and meta-analysis. Rev Med Virol.
;30(6):1-9.
Heink S., Yogev N., Garbers C. Trans-presentation of IL-6 by
dendritic cells is required for the priming of pathogenic
TH17 cells [published correction appears in Nat Immunol.
Mar 22;18(4):474] Nat Immunol. 2017;18(1):74-85.
Chen X., Zhao B., Gu Y., Chen Y., Xiong J., Feng J. Detectable
serum SARS-CoV-2 viral load (RNAaemia) is closely
associated with drastically elevated interleukin 6 (IL-6)
level in critically ill COVID-19 patients. bioRxiv. 2020.
Wang H., Luo S., Shen Y., Li M., Zhang Z., Dong Y. Multiple
enzyme release, inflammation storm and
hypercoagulability are prominent indicators for disease
progression in COVID-19: a multi-centered, correlation
study with CT imaging score. SSRN. 2020
Xia C., Liu Y., Chen Z., Zheng M. Involvement of Interleukin 6
in Hepatitis B Viral Infection. Cell
PhysiolBiochem. 2015;37(2):677-686.
Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui
Huang, Noam D. Beckmann, Sharon Nirenberg, Bo
Wang, Yonit Lavin, Talia H. Swartz, DeepuMadduri,
Aryeh Stock, Thomas U. Marron, Hui Xie, Manishkumar
Patel, Kevin Tuballes, Oliver Van Oekelen, Adeeb
Rahman, Patricia Kovatch, Judith A. Aberg, Eric Schadt,
SundarJagannath, MadhuMazumdar, Alexander W.
Charney, Adolfo Firpo-Betancourt, Damodara Rao
Mendu, ...Sacha Gnjatic Show authors Nature Medicine
volume 26, pages1636-1643 (2020)
Herold T., Jurinovic V., Arnreixh C., Hellmuth J.C., von
Bergwett M. Level of IL-6 predicts respiratory failure in
hospiralized symptomatic COVID-19
patients. medRxiv. 2020.
Wan S., Yi Q., Fan S. Relationships among lymphocyte
subsets, cytokines, and the pulmonary inflammation
index in coronavirus (COVID-19) infected patients. Br J
Haematol. 2020;189(3):428-437.
Coomes E.A., Haghbayan H. Interleukin-6 in COVID-19: a
systemic review and meta-analysis. med Rxiv. 2020.
P.A. Ascierto, B. Fu, H. Wei, IL-6 modulation for COVID-19:
the right patients at the right time? J. Immunother.
Cancer 9 (4) (2021), eOO2285 https://doi: 10.1136/jitc-
-002285.
M. Effenberger, C. Grander, F. Grabherr, A. Griesmacher, T.
Ploner, F. Hartig, R. Bellmann-Weiler, M. Joannidis, H.
Zoller, G. Weiss, Systemic inflammation as fuel for acute
liver injury in COVID-19, Dig. Liver Dis. 53 (2) (2021) 158-
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
